Invitrogen™ PD-L1/CD47 Biosimilar Recombinant Human Monoclonal Antibody

Description

PD-L1/CD47 Biosimilar Recombinant Monoclonal Antibody for SPR, Flow, ELISA, Functional

Programmed Cell Death Ligand 1 (PD-L1) and Cluster of Differentiation 47 (CD47) are two significant molecules involved in the immune evasion mechanisms of cancer cells. PD-L1, encoded by the CD274 gene, is a transmembrane protein that interacts with the PD-1 receptor on T-cells, leading to the inhibition of T-cell activation and proliferation, thus allowing cancer cells to evade immune detection. This pathway is targeted by several immunotherapeutic drugs, including pembrolizumab and nivolumab, which have shown effectiveness in treating various cancers. On the other hand, CD47, a transmembrane protein encoded by the CD47 gene, sends a don't eat me signal by binding to the Signal-Regulatory Protein Alpha (SIRP alpha) on myeloid cells, thereby inhibiting phagocytosis of cancer cells by macrophages. Overexpression of CD47 is observed in many tumors and is associated with poor prognosis. Therapeutic strategies targeting the CD47-SIRP alpha axis are being developed to enhance the phagocytosis of cancer cells and improve anti-tumor immunity. Both PD-L1 and CD47 play crucial roles in the tumor microenvironment by helping cancer cells evade immune destruction, and targeting these pathways has become a promising approach in cancer immunotherapy.